Increasing social vulnerability is associated with significant decreases in surveillance and survival time among pediatric patients with head and neck cancers.
Among patients with head and neck cancer, smoking cessation for more than 10 years is associated with reduced overall mortality and cancer-specific mortality.
Adding docetaxel to radiation improves outcomes for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, a phase 2/3 trial suggests.
In a first-in-human trial of patients with solid tumors, a MYC inhibitor appeared tolerable and enabled nearly half of evaluable patients to maintain stable disease.
Durvalumab plus IMRT proved no more effective than cetuximab plus IMRT in patients with treatment-naïve, locoregionally advanced head and neck squamous cell carcinoma.